Takeda signs exclusive agreement with AC Immune Ink for Alzheimer’s disease immunotherapy

Takeda and AC Immune SA have entered into an exclusive, global option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24.060 for the treatment of Alzheimer’s disease.

Under the agreement, AC Immune will receive an upfront payment of $100 million and will be eligible to receive option exercise fees and additional potential development, commercial and sales milestones (if all relevant milestones are achieved), up to an amount of approximately $2.1 billion. Upon commercialization, AC Immune will be entitled to royalties on global sales.

ACI-24.060 is an anti-Abeta active immunotherapy candidate designed to induce a robust antibody response against the toxic form of Abeta, which is thought to promote plaque formation and Alzheimer’s disease progression. By inducing plaque clearance in the brain and inhibiting plaque formation, ACI-24.060 has the potential to delay or slow the progression of Alzheimer’s disease. ACI-24.060 is being studied in the ongoing ABATE Phase 1b/2 trial to evaluate the safety, tolerability, immune response of an investigational immunotherapy in subjects with prodromal Alzheimer’s disease and adults with Down syndrome. properties and pharmacodynamic effects.

AC Immune will be responsible for completing the ABATE trial. Upon exercise of the option, Takeda will conduct and fund all further clinical development and be responsible for all global regulatory activities as well as global commercialization.

Dr. Andrea Pfeifer, CEO, AC Immune. “This agreement allows us to leverage the development expertise, strategic vision and financial capabilities of an established organization that has demonstrated its ability to execute the comprehensive global program required for Alzheimer’s Phase 3 trials, while allowing us to focus on Complete Phase 1b/2 development and accelerate our efforts to replicate this success by increasing funding for our early product lines.

“Combining AC Immune’s extensive experience in active immunotherapy approaches with Takeda’s expertise in neuroscience drug development and commercialization, we have a Incredible opportunities to make a real impact on the world.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Back To Top